Drug Combination Shows Benefit in RAS-Driven Cancers

Excerpt:

“Cancers driven by the RAS oncogene are aggressive and difficult to treat, and thus far precision drugs haven’t been able to target the mutant RAS gene successfully.

“But in a presentation at the American Association for Cancer Research Annual Meeting on Monday, April 3, 2017 at 10:30 a.m., in Washington DC, Dana-Farber Cancer Institute scientists said a number of in a small study with RAS-driven lung, ovarian, and thyroid cancers got long-term clinical benefit from a combination of two drugs that targeted molecular pathways controlled by the RAS gene.

” ‘Between one-quarter and one-third of patients got long-term clinical benefit,’ said Geoffrey Shapiro, MD, PhD, director of Dana-Farber’s Early Drug Development Center. ‘Several patients were on the drugs for more than a year, and one patient has been on treatment for two and a half years. And these were heavily-treated patients without many options.’ ”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.